Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
48,884,398
-
Share change
-
+1,015,338
-
Total reported value
-
$533,310,908
-
Put/Call ratio
-
27%
-
Price per share
-
$10.91
-
Number of holders
-
134
-
Value change
-
+$12,463,535
-
Number of buys
-
71
-
Number of sells
-
56
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q4 2022
As of 31 Dec 2022,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
134 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,884,398 shares.
The largest 10 holders included
STATE STREET CORP, BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, RTW INVESTMENTS, LP, VANGUARD GROUP INC, JOHNSON & JOHNSON, MORGAN STANLEY, Bain Capital Life Sciences Investors, LLC, CITADEL ADVISORS LLC, and MARSHALL WACE, LLP.
This page lists
135
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.